Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
07:30am, Thursday, 02'nd Apr 2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new paye
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 31'st Mar 2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceut
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
07:30am, Thursday, 26'th Mar 2026
HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radi
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
07:30am, Thursday, 19'th Mar 2026
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization Heal
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
08:27pm, Thursday, 12'th Mar 2026
Plus Therapeutics (PSTV) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.67 per share a year ago.
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radi
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
07:30am, Wednesday, 25'th Feb 2026
Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization tracking Unlocks market access and growth potent
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript
11:34am, Thursday, 22'nd Jan 2026
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
04:15pm, Wednesday, 21'st Jan 2026
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutical
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges
11:36am, Wednesday, 14'th Jan 2026
Plus Therapeutics Inc. (NASDAQ: PSTV) stock is down during trading session on Wednesday following the company's announcement of a public offering.
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
08:00am, Wednesday, 14'th Jan 2026
HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutical
Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday
02:23am, Monday, 12'th Jan 2026
US stock futures down, investors focus on Sify, Boot Barn, Wealthfront, Plus Therapeutics, Solowin; Citigroup expected to report Q4 earnings.
HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and rad
Plus Therapeutics Expands CNSide Assay Platform to State of California
07:30am, Thursday, 11'th Dec 2025
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
07:30am, Tuesday, 09'th Dec 2025
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics wit
